Regional Cancer Care Associates - Central Jersey
Welcome,         Profile    Billing    Logout  
 17 Trials 
29 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moskowitz, Craig
S2308, NCT06337318: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Recruiting
3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
03/32
03/32
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, Canada, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
NCT06377566: A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
2
71
US
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Hodgkin Lymphoma
04/27
04/27
NCT03179917: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Active, not recruiting
2
22
US
Pembrolizumab, Involved Site Radiation Therapy
Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
06/26
06/26
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
257
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/25
08/25
NCT05886036: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Recruiting
2
70
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
10/26
10/26
SGN35C-001, NCT06254495: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
PF-08046044/SGN-35C
Seagen, a wholly owned subsidiary of Pfizer
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
04/28
04/29
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
ULTRA-HFIB, NCT04182620: Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation

Active, not recruiting
N/A
160
US
renal denervation, Catheter ablation
Vivek Reddy
Atrial Fibrillation
03/25
03/25
LIFE-L, NCT05839210: Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

Recruiting
N/A
120
US
LIFE-L Mediterranean Diet, LIFE-L Home-Based Exercise Program, Supportive Materials
University of Miami
Non Hodgkin Lymphoma, Hodgkin Lymphoma
04/25
04/25
Kim, Youn H
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
NCT04256018: Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Recruiting
2
30
US
Mogamulizumab, LD TSEBT, Low-Dose (LD) Total skin electron beam therapy (TSEBT)
Stanford University
Sezary Syndrome, Mycosis Fungoides
12/26
12/26
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/25
07/25
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT02848274: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Recruiting
N/A
2000
Europe, Japan, US, RoW
Stanford University
Mycosis Fungoides, Non-Hodgkin's Lymphoma
03/27
03/27
Feldman, Tatyana
NCT03712202: Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Active, not recruiting
2
155
US
Bleomycin, BLEO, BLM, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Vinblastine, Vincaleucoblastine, VLB
City of Hope Medical Center, National Cancer Institute (NCI)
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
12/24
12/24
NCT04561206: Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma

Recruiting
2
31
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Relapsed Classic Hodgkin Lymphoma
10/26
10/26
NCT03728972: Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Active, not recruiting
2
19
US
Pembrolizumab
Memorial Sloan Kettering Cancer Center
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
11/25
11/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT05967416: Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
1
24
US
SIRPant-M, External-beam radiotherapy (XRT)
SIRPant Immunotherapeutics, Inc.
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
06/25
12/25
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT02848274: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Recruiting
N/A
2000
Europe, Japan, US, RoW
Stanford University
Mycosis Fungoides, Non-Hodgkin's Lymphoma
03/27
03/27
Lynch, Terry-Ann
SGN35C-001, NCT06254495: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
PF-08046044/SGN-35C
Seagen, a wholly owned subsidiary of Pfizer
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
04/28
04/29
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
Chen, Tara
SGN35C-001, NCT06254495: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
PF-08046044/SGN-35C
Seagen, a wholly owned subsidiary of Pfizer
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
04/28
04/29
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
Daszkiewicz, Greg
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Moskowitz, Craig
S2308, NCT06337318: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

Recruiting
3
600
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Classic Follicular Lymphoma, Follicular Lymphoma With Unusual Cytological Features
03/32
03/32
RADAR, NCT04685616: Brentuximab Vedotin in Early Stage Hodgkin Lymphoma

Recruiting
3
1042
Europe, Canada, US, RoW
Involved site radiotherapy, Doxorubicin, Bleomycin, Brentuximab vedotin, Vinblastine, Dacarbazine, Haematopoietic growth factor, Filgrastim, G-CSF, Pegfilgrastim
University College, London, Takeda, University of Miami, European Organisation for Research and Treatment of Cancer - EORTC, Australasian Leukaemia and Lymphoma Group, Seagen Inc., Canadian Cancer Trials Group
Hodgkin Lymphoma
09/30
09/32
NCT06377566: A Study of BV-AVD in People With Bulky Hodgkin Lymphoma

Recruiting
2
71
US
Brentuximab vedotin, Doxorubicin, Vinblastine, Dacarbazine, Pembrolizumab, Gemcitabine, Vinorelbine, FDG-PET/CT scan
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Hodgkin Lymphoma
04/27
04/27
NCT03179917: Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Active, not recruiting
2
22
US
Pembrolizumab, Involved Site Radiation Therapy
Memorial Sloan Kettering Cancer Center
Hodgkin Lymphoma
06/26
06/26
NCT03618550: Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

Recruiting
2
257
US
pembrolizumab, gemcitabine, vinorelbine, liposomal doxorubicin, Stem cell mobilization and collection
Memorial Sloan Kettering Cancer Center, Merck Sharp & Dohme LLC
Hodgkin Lymphoma, Relapsed or Refractory Hodgkin Lymphoma
08/25
08/25
NCT05886036: Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Recruiting
2
70
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Mosunetuzumab, Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody BTCT4465A, BTCT 4465A, BTCT-4465A, BTCT4465A, CD20/CD3 BiMAb BTCT4465A, Lunsumio, Mosunetuzumab-axgb, RG 7828, RG-7828, RG7828, RO7030816, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, PT, Rituximab, ABP 798, ABP-798, ABP798, BI 695500, BI-695500, BI695500, Blitzima, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT P10, CT-P10, CTP10, GP 2013, GP-2013, GP2013, IDEC 102, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, IDEC102, Ikgdar, Mabtas, MabThera, Monoclonal Antibody IDEC-C2B8, PF 05280586, PF-05280586, PF05280586, Riabni, Ritemvia, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar GP2013, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-blit, Rituximab-pvvr, Rituximab-rite, Rituximab-rixa, Rituximab-rixi, Rixathon, Riximyo, RTXM 83, RTXM-83, RTXM83, Ruxience, Truxima, Rituximab and Hyaluronidase Human, Rituxan Hycela, Rituximab Plus Hyaluronidase, Rituximab/Hyaluronidase, Rituximab/Hyaluronidase Human
National Cancer Institute (NCI)
Nodular Lymphocyte Predominant B-Cell Lymphoma, Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma, Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma
10/26
10/26
SGN35C-001, NCT06254495: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
PF-08046044/SGN-35C
Seagen, a wholly owned subsidiary of Pfizer
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
04/28
04/29
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
ULTRA-HFIB, NCT04182620: Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation

Active, not recruiting
N/A
160
US
renal denervation, Catheter ablation
Vivek Reddy
Atrial Fibrillation
03/25
03/25
LIFE-L, NCT05839210: Lifestyle Intervention of Food and Exercise for Lymphoma Survivors

Recruiting
N/A
120
US
LIFE-L Mediterranean Diet, LIFE-L Home-Based Exercise Program, Supportive Materials
University of Miami
Non Hodgkin Lymphoma, Hodgkin Lymphoma
04/25
04/25
Kim, Youn H
TELLOMAK, NCT03902184 / 2018-003969-33: IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Checkmark Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Dec 2022 - Dec 2022: Preliminary efficacy data from TELLOMAK trial for Sezary syndrome at ASH 2022
Checkmark Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Sep 2022 - Sep 2022: Data from stage 2 cohort of TELLOMAK trial for mycosis fungoides
Checkmark Preliminary efficacy data from stage 1 of TELLOMAK trial for mycosis fungoides at ICML 2021
More
Active, not recruiting
2
170
Europe, US
IPH4102, lacutamab
Innate Pharma
Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome
10/23
01/26
NCT04256018: Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome

Recruiting
2
30
US
Mogamulizumab, LD TSEBT, Low-Dose (LD) Total skin electron beam therapy (TSEBT)
Stanford University
Sezary Syndrome, Mycosis Fungoides
12/26
12/26
NCT03587844: Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

Recruiting
2
58
US
brentuximab vedotin
Memorial Sloan Kettering Cancer Center, Seagen Inc.
Mycosis Fungoides, Lymphomatoid Papulosis, Sezary Syndrome
07/25
07/25
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT02848274: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Recruiting
N/A
2000
Europe, Japan, US, RoW
Stanford University
Mycosis Fungoides, Non-Hodgkin's Lymphoma
03/27
03/27
Feldman, Tatyana
NCT03712202: Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Active, not recruiting
2
155
US
Bleomycin, BLEO, BLM, Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Dacarbazine, 4-(Dimethyltriazeno)imidazole-5-carboxamide, 5-(Dimethyltriazeno)imidazole-4-carboxamide, Asercit, Biocarbazine, Dacarbazina, Dacarbazina Almirall, Dacarbazine - DTIC, Dacatic, Dakarbazin, Deticene, Detimedac, DIC, Dimethyl (triazeno) imidazolecarboxamide, Dimethyl Triazeno Imidazol Carboxamide, Dimethyl Triazeno Imidazole Carboxamide, dimethyl-triazeno-imidazole carboxamide, Dimethyl-triazeno-imidazole-carboximide, DTIC, DTIC-Dome, Fauldetic, Imidazole Carboxamide, Imidazole Carboxamide Dimethyltriazeno, WR-139007, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Quality-of-Life Assessment, Quality of Life Assessment, Vinblastine, Vincaleucoblastine, VLB
City of Hope Medical Center, National Cancer Institute (NCI)
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
12/24
12/24
NCT04561206: Brentuximab Vedotin and Nivolumab for the Treatment of Patients with Relapsed/refractory Classical Hodgkin Lymphoma

Recruiting
2
31
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Relapsed Classic Hodgkin Lymphoma
10/26
10/26
NCT03728972: Study of Pembrolizumab in Patients With Early-Stage NK/T-cell Lymphoma, Nasal Type

Active, not recruiting
2
19
US
Pembrolizumab
Memorial Sloan Kettering Cancer Center
NK/T-Cell Lymphoma of Nasal Cavity (Diagnosis), NK/T-Cell Lymphoma of Nasopharynx (Diagnosis)
11/25
11/25
VT3996-201, NCT03397706: Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV+ Lymphoid Malignancies

Completed
1/2
64
US, RoW
VRx-3996 and valganciclovir, nanatinostat, ganciclovir, Chroma (CHR)-3996
Viracta Therapeutics, Inc.
Epstein-Barr Virus-Associated Lymphoma, Lymphoproliferative Disorders
04/23
05/23
CA209-447, NCT03033914: A(B)VD Followed by Nivolumab as Frontline Therapy for Higher Risk Patients With Classical Hodgkin Lymphoma (HL)

Active, not recruiting
1/2
82
Canada, US
doxorubicin, Bleomycin, vinblastine, dacarbazine, Nivolumab
Memorial Sloan Kettering Cancer Center, Bristol-Myers Squibb, Barbara Ann Karmanos Cancer Institute, British Columbia Cancer Agency
Hodgkin Lymphoma
01/26
01/26
TRANSCEND-CLL-004, NCT03331198: Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Checkmark Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Jan 2023 - Jan 2023: Data from TRANSCEND-CLL-004 trial for r/r CLL or SLL
Checkmark From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Dec 2019 - Dec 2019: From TRANSCEND-CLL-004 trial in CLL at ASH 2019
Hourglass Oct 2018 - Dec 2018 : Completion of enrollment in P2 TRANSCEND WORLD trial for 3L DLBCL
More
Recruiting
1/2
320
Canada, US
JCAR017 (lisocabtagene maraleucel), JCAR017 (lisocabtagene maraleucel) + ibrutinib, JCAR017 (lisocabtagene maraleucel) + venetoclax
Juno Therapeutics, a Subsidiary of Celgene
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Small Lymphocytic
11/27
11/27
NCT05967416: Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
1
24
US
SIRPant-M, External-beam radiotherapy (XRT)
SIRPant Immunotherapeutics, Inc.
Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma
06/25
12/25
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
NCT02848274: ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome

Recruiting
N/A
2000
Europe, Japan, US, RoW
Stanford University
Mycosis Fungoides, Non-Hodgkin's Lymphoma
03/27
03/27
Lynch, Terry-Ann
SGN35C-001, NCT06254495: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
PF-08046044/SGN-35C
Seagen, a wholly owned subsidiary of Pfizer
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
04/28
04/29
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
Chen, Tara
SGN35C-001, NCT06254495: A Safety Study of PF-08046044/SGN-35C in Adults With Advanced Cancers

Recruiting
1
170
Europe, US
PF-08046044/SGN-35C
Seagen, a wholly owned subsidiary of Pfizer
Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Large-Cell, Anaplastic
04/28
04/29
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30
Daszkiewicz, Greg
NCT06120504: A Safety Study of SGN-35T in Adults With Advanced Cancers

Recruiting
1
110
Europe, Canada, US
SGN-35T
Seagen, a wholly owned subsidiary of Pfizer
Lymphoma, T-Cell, Cutaneous, Hodgkin Disease, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin
06/27
04/30

Download Options